-
Something wrong with this record ?
Dimethyl fumarate attenuates bile acid retention and liver fibrosis in a mouse model of cholestasis
H. Lastuvkova, E. Dohnalkova, DF. Manna, J. Cermanova, J. Mokry, J. Pejchal, P. Hirsova, P. Nachtigal, I. Pavkova, M. Bajnokova, L. Smutna, A. Stefela, R. Kamaraj, L. Jandova, M. Uher, P. Pavek, S. Micuda, M. Hroch
Language English Country United States
Document type Journal Article
Grant support
SVV-2023-260656
Grantová Agentura, Univerzita Karlova (GA UK)
SVV-260663
Grantová Agentura, Univerzita Karlova (GA UK)
GAUK 116824
Grantová Agentura, Univerzita Karlova (GA UK)
UNCE24/MED/008
Grantová Agentura, Univerzita Karlova (GA UK)
CZ.02.01.01/00/22_008/0004607
EC | European Regional Development Fund (ERDF)
DZRO-FVZ22-ZHN II
Ministerstvo Obrany České Republiky (MOČR)
22-05167S
Grantová Agentura České Republiky (GAČR)
R01DK130884
HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- MeSH
- Cholestasis * drug therapy metabolism chemically induced MeSH
- Dimethyl Fumarate * pharmacology therapeutic use MeSH
- Liver Cirrhosis * metabolism drug therapy pathology etiology MeSH
- Hepatic Stellate Cells drug effects metabolism MeSH
- Liver * metabolism drug effects pathology MeSH
- Disease Models, Animal MeSH
- Mice, Inbred C57BL MeSH
- Mice MeSH
- Bile Acids and Salts * metabolism MeSH
- Animals MeSH
- Check Tag
- Male MeSH
- Mice MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
Cholestatic liver diseases are characterized by intrahepatic accumulation of bile acids (BAs), exacerbating liver inflammation, and fibrosis. Dimethyl fumarate (DMF) is a clinically approved anti-inflammatory drug that demonstrated protective effects in several experimental models of liver injury. Still, its effect on BA homeostasis and liver fibrosis has not been thoroughly studied. Herein, we hypothesized that DMF could improve BA homeostasis and mitigate the progression of cholestasis-induced liver fibrosis. The DMF was administered to mice with 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC)-induced cholestasis for 4 wk. The content of individual BAs in the plasma, liver, bile, intestine, and feces was measured using the LC-MS method alongside the analysis of liver phenotype and related executive and regulatory pathways. The DMF slowed down the progression of DDC-induced liver fibrosis by suppressing hepatic stellate cell and macrophage activation and by reducing c-Jun N-terminal kinase phosphorylation. Notably, DMF reduced BA cumulation in the plasma and liver of cholestatic mice by increasing BA fecal excretion via their reduced Bacteroidetes phyla-mediated deconjugation in the intestine. In addition, DMF was identified as the antagonist of the mouse farnesoid X receptor in enterocytes. In conclusion, DMF alleviates DDC-induced cholestatic liver injury through pleiotropic action leading to significant anti-inflammatory and antifibrotic activity of the agent. In addition, DMF mitigates BA retention in the liver and plasma by increasing their fecal excretion in cholestatic mice. These findings suggest that DMF warrants further investigation as a potential therapeutic agent for human chronic fibrosing cholestatic liver disorders.NEW & NOTEWORTHY Chronic cholestatic cholangiopathies present a therapeutic challenge due to their complex pathophysiology, where the accumulation of bile acids plays a crucial role. In this study, we found that dimethyl fumarate attenuated cholestatic liver damage in a murine model through its significant anti-inflammatory and antifibrotic activity supported by reduced bile acid accumulation in the plasma and liver via their increased fecal excretion.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25015866
- 003
- CZ-PrNML
- 005
- 20250731091312.0
- 007
- ta
- 008
- 250708s2025 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1152/ajpgi.00262.2024 $2 doi
- 035 __
- $a (PubMed)40210415
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Lastuvkova, Hana $u Department of Pharmacology, Faculty of Medicine in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic
- 245 10
- $a Dimethyl fumarate attenuates bile acid retention and liver fibrosis in a mouse model of cholestasis / $c H. Lastuvkova, E. Dohnalkova, DF. Manna, J. Cermanova, J. Mokry, J. Pejchal, P. Hirsova, P. Nachtigal, I. Pavkova, M. Bajnokova, L. Smutna, A. Stefela, R. Kamaraj, L. Jandova, M. Uher, P. Pavek, S. Micuda, M. Hroch
- 520 9_
- $a Cholestatic liver diseases are characterized by intrahepatic accumulation of bile acids (BAs), exacerbating liver inflammation, and fibrosis. Dimethyl fumarate (DMF) is a clinically approved anti-inflammatory drug that demonstrated protective effects in several experimental models of liver injury. Still, its effect on BA homeostasis and liver fibrosis has not been thoroughly studied. Herein, we hypothesized that DMF could improve BA homeostasis and mitigate the progression of cholestasis-induced liver fibrosis. The DMF was administered to mice with 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC)-induced cholestasis for 4 wk. The content of individual BAs in the plasma, liver, bile, intestine, and feces was measured using the LC-MS method alongside the analysis of liver phenotype and related executive and regulatory pathways. The DMF slowed down the progression of DDC-induced liver fibrosis by suppressing hepatic stellate cell and macrophage activation and by reducing c-Jun N-terminal kinase phosphorylation. Notably, DMF reduced BA cumulation in the plasma and liver of cholestatic mice by increasing BA fecal excretion via their reduced Bacteroidetes phyla-mediated deconjugation in the intestine. In addition, DMF was identified as the antagonist of the mouse farnesoid X receptor in enterocytes. In conclusion, DMF alleviates DDC-induced cholestatic liver injury through pleiotropic action leading to significant anti-inflammatory and antifibrotic activity of the agent. In addition, DMF mitigates BA retention in the liver and plasma by increasing their fecal excretion in cholestatic mice. These findings suggest that DMF warrants further investigation as a potential therapeutic agent for human chronic fibrosing cholestatic liver disorders.NEW & NOTEWORTHY Chronic cholestatic cholangiopathies present a therapeutic challenge due to their complex pathophysiology, where the accumulation of bile acids plays a crucial role. In this study, we found that dimethyl fumarate attenuated cholestatic liver damage in a murine model through its significant anti-inflammatory and antifibrotic activity supported by reduced bile acid accumulation in the plasma and liver via their increased fecal excretion.
- 650 _2
- $a zvířata $7 D000818
- 650 12
- $a žlučové kyseliny a soli $x metabolismus $7 D001647
- 650 12
- $a cholestáza $x farmakoterapie $x metabolismus $x chemicky indukované $7 D002779
- 650 12
- $a dimethyl fumarát $x farmakologie $x terapeutické užití $7 D000069462
- 650 _2
- $a myši $7 D051379
- 650 12
- $a jaterní cirhóza $x metabolismus $x farmakoterapie $x patologie $x etiologie $7 D008103
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a modely nemocí na zvířatech $7 D004195
- 650 12
- $a játra $x metabolismus $x účinky léků $x patologie $7 D008099
- 650 _2
- $a myši inbrední C57BL $7 D008810
- 650 _2
- $a jaterní hvězdicovité buňky $x účinky léků $x metabolismus $7 D055166
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Dohnalkova, Ester $u Department of Biological and Medical Sciences, Faculty of Pharmacy in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic
- 700 1_
- $a Manna, Dina Faeq $u Department of Pharmacology, Faculty of Medicine in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic $1 https://orcid.org/0009000394846209
- 700 1_
- $a Cermanova, Jolana $u Department of Pharmacology, Faculty of Medicine in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic
- 700 1_
- $a Mokry, Jaroslav $u Department of Histology and Embryology, Faculty of Medicine in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic
- 700 1_
- $a Pejchal, Jaroslav $u Department of Toxicology and Military Pharmacy, Military Faculty of Medicine, University of Defence, Hradec Kralove, Czech Republic $1 https://orcid.org/0000000322287922 $7 xx0102560
- 700 1_
- $a Hirsova, Petra $u Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, United States $1 https://orcid.org/0000000304940924 $7 xx0104768
- 700 1_
- $a Nachtigal, Petr $u Department of Biological and Medical Sciences, Faculty of Pharmacy in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic
- 700 1_
- $a Pavkova, Ivona $u Department of Molecular Pathology and Biology, Military Faculty of Medicine, University of Defence in Brno, Hradec Kralove, Czech Republic
- 700 1_
- $a Bajnokova, Maria $u Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic $1 https://orcid.org/0009000017984630
- 700 1_
- $a Smutna, Lucie $u Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic $1 https://orcid.org/0000000239414193 $7 uk20211104952
- 700 1_
- $a Stefela, Alzbeta $u Department of Physiology, Faculty of Medicine in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic $1 https://orcid.org/0000000314716248
- 700 1_
- $a Kamaraj, Rajamanikkam $u Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic $1 https://orcid.org/0000000171150178
- 700 1_
- $a Jandova, Lenka $u Department of Pharmacology, Faculty of Medicine in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic $1 https://orcid.org/0009000609317815
- 700 1_
- $a Uher, Martin $u Department of Medical Biochemistry, Faculty of Medicine in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic
- 700 1_
- $a Pavek, Petr $u Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic $1 https://orcid.org/0000000187694196 $7 xx0093070
- 700 1_
- $a Micuda, Stanislav $u Department of Pharmacology, Faculty of Medicine in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic $1 https://orcid.org/0000000277737161 $7 jn20010309083
- 700 1_
- $a Hroch, Milos $u Department of Medical Biochemistry, Faculty of Medicine in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic $1 https://orcid.org/0000000255832942 $7 xx0076212
- 773 0_
- $w MED00000287 $t American journal of physiology: Gastrointestinal and liver physiology $x 1522-1547 $g Roč. 328, č. 5 (2025), s. G558-G577
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/40210415 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250708 $b ABA008
- 991 __
- $a 20250731091307 $b ABA008
- 999 __
- $a ok $b bmc $g 2366594 $s 1252991
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2025 $b 328 $c 5 $d G558-G577 $e 20250410 $i 1522-1547 $m American journal of physiology: Gastrointestinal and liver physiology $n Am J Physiol Gastrointest Liver Physiol $x MED00000287
- GRA __
- $a SVV-2023-260656 $p Grantová Agentura, Univerzita Karlova (GA UK)
- GRA __
- $a SVV-260663 $p Grantová Agentura, Univerzita Karlova (GA UK)
- GRA __
- $a GAUK 116824 $p Grantová Agentura, Univerzita Karlova (GA UK)
- GRA __
- $a UNCE24/MED/008 $p Grantová Agentura, Univerzita Karlova (GA UK)
- GRA __
- $a CZ.02.01.01/00/22_008/0004607 $p EC | European Regional Development Fund (ERDF)
- GRA __
- $a DZRO-FVZ22-ZHN II $p Ministerstvo Obrany České Republiky (MOČR)
- GRA __
- $a 22-05167S $p Grantová Agentura České Republiky (GAČR)
- GRA __
- $a R01DK130884 $p HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- LZP __
- $a Pubmed-20250708
